Optimized Fc variants
The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
1. A method of altering effector function in a subject, comprising administering to the subject a polypeptide comprising an Fc variant of a human parent IgG1 Fc polypeptide, wherein said Fc variant comprises an amino acid substitution in the Fc region of said parent Fc polypeptide at position 264, wherein said numbering is according to the EU index in Kabat.
2. The method according to claim 1 , wherein said polypeptide is an antibody.
3. The method according to claim 1 , wherein said polypeptide comprises an engineered glycoform.
4. The method according to claim 1 , wherein said amino acid substitution is 264I.
5. The method according to claim 1 , wherein said amino acid substitution is 264I and said Fc variant exhibits reduced binding to FcγRIIIa as compared to the human parent IgG1 Fc polypeptide.
6. The method according to claim 1 , wherein said amino acid substitution is 264T.
7. The method according to claim 1 , wherein said amino acid substitution is 264T and said Fc variant exhibits increased binding to FcγRIIIa as compared to the human parent IgG1 Fc polypeptide.
8. The method according to claim 1 , wherein said amino acid substitution is 264F.
9. The method according to claim 1 , wherein said amino acid substitution is 264F and said Fc variant exhibits reduced binding to FcγRIIIa as compared to the human parent IgG1 Fc polypeptide.
10. The method according to claim 1 , wherein said amino acid substitution is 264M.
11. The method according to claim 1 , wherein said amino acid substitution is 264M and said Fc variant exhibits reduced binding to FcγRIIIa as compared to the human parent IgG1 Fc polypeptide.
12. The method according to claim 1 , wherein said amino acid substitution is 264Y.
13. The method according to claim 1 , wherein said amino acid substitution is 264Y and said Fc variant exhibits reduced binding to FcγRIIIa as compared to the human parent IgG1 Fc polypeptide.
14. The method according to claim 1 , wherein said amino acid substitution is 264W.
15. The method according to claim 1 , wherein said amino acid substitution is 264W and said Fc variant exhibits reduced binding to FcγRIIIa as compared to the human parent IgG1 Fc polypeptide.
16. The method according to claim 1 , wherein said amino acid substitution is 264R.
17. The method according to claim 1 , wherein said amino acid substitution is 264R and said Fc variant exhibits increased binding to FcγRIIIa as compared to the human parent IgG1 Fc polypeptide.
18. The method according to claim 1 , wherein said amino acid substitution is 264E.
19. The method according to claim 1 , wherein said amino acid substitution is 264E and said Fc variant exhibits reduced binding to FcγRIIIa as compared to the human parent IgG1 Fc polypeptide.
20. The method according to claim 1 , wherein said amino acid substitution is 243A.
21. The method according to claim 1 , wherein said amino acid substitution is 243A and said Fc variant exhibits reduced binding to FcγRIIIa as compared to the human parent IgG1 Fc polypeptide.
22. The method according to claim 2 , wherein said antibody has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, IgE, HLA-DR, TNFalpha, MUC18, prostate specific membrane antigen (PMSA) and VEGF.
23. The method according to claim 22 , wherein said antibody has specificity for Her2/neu.
24. The method according to claim 1 , wherein said subject has cancer.
25. The method according to claim 1 , wherein said subject has an autoimmune disorder.
26. The method according to claim 1 , wherein said subject has an inflammatory disorder.